Pre-series A investment in THE PHAGE, a provider of personalized blood glucose control solutions
Genesia Ventures has invested in THE PHAGE, a company offering personalized blood glucose control solutions.
About THE PHAGE
THE PHAGE is a startup on a mission to “build a recommendation-based society rooted in biological needs.” They aim to introduce new medical and healthcare experiences by analyzing the relationship between daily biometric data and lifestyle habits, and offering personalized, optimized recommendations tailored to each individual.
From the vast array of biometric information available, THE PHAGE initially focused on blood glucose levels due to their high sensitivity to lifestyle factors like diet and exercise. Blood glucose levels are dynamic and change in response to multiple factors. Until now, accurately interpreting these changes has been challenging without the expertise of medical professionals.
▼ Research and Development support services
THE PHAGE provides R&D support for innovative technologies and services in collaboration with companies, including medical and food manufacturers. They have recently formed a strategic alliance with TOPPAN for health food R&D support. Additionally, they are partnering with Meiji to explore diverse health benefits of food products.
▼ Diabetes treatment support service Glucose Flight®
Glucose Flight®, developed and provided by THE PHAGE, is a comprehensive diabetes treatment support system offering personalized lifestyle recommendations. It analyzes individual biometric data to propose optimized treatment indices, encouraging users to manage their blood glucose levels independently. The system also aids medical professionals in delivering precise nutritional guidance tailored to each patient’s unique lifestyle and eating habits.
Background and purpose of fundraising
The funds raised will be used to develop Glucose Flight® and strengthen the company’s recruitment and organizational structure. The company aims to expand its AI-based diabetes care business in the healthcare sector — a field demanding high ethical standards and quality control. Additionally, they will focus on R&D support in medical and healthcare areas, including food, medicine, and insurance. The ultimate goal is to scale these operations commercially, enabling large-scale, day-to-day implementation.
Rapidly upgrading existing business operations is crucial, but equally important is integrating expert knowledge to develop systems through ongoing product refinement. THE PHAGE welcomes the collaboration of diverse professionals who are passionate about advancing data-driven health initiatives and medical digital transformation through AI development in healthcare.
About the Investment
Koki Mizutani, Investment Manager, Genesia Ventures
Following our investment in the seed round, we are happy to announce our role as the lead investor in this latest round of financing. This project, spearheaded by Tokunaga and Shiren, has been years in the making since the company’s establishment. Thanks to multiple breakthroughs since the seed round, it has finally entered a phase where significant progress in social implementation is imminent. Together with our new shareholders — who will be invaluable allies — we are committed to working as a unified team to deliver this long-awaited outcome for humanity.
Company Profile
Company Name : THE PHAGE, Inc.
WEB : https://thephage.life/
Established : July 15, 2021
Location ：5F Yamaguchi Building, 3-17-4 Shibuya, Shibuya-ku, Tokyo
Representative ：Shohei Tokunaga
